Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132968) titled 'Phase II Study of Ivonescimab plus GEMOX for Neoadjuvant and Conversion Therapy in BTC' on Sept. 20.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Confirmed by histology and cytology as biliary tract cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder cancer), and evaluated by imaging as locally advanced or accompanied by oligometastasis (defined as stage IIIA or above lesions according to the AJCC-8 staging system).
Intervention:
Neoadjuvant cohort:Ivonescimab combined with GEMOX c...